“…However, the appropriateness of administering chemotherapy close to death should be carefully evaluated [52], given that receiving chemotherapy at the EOL is not influenced by the cancer's responsiveness to chemotherapy [41] and that the more intense use of chemotherapy by medical oncologists does not prolong survival [56]. Furthermore, the cumulative use of chemotherapy may take a negative toll, leading to more complications, subsequent frequent ER visits and admissions and ICU care, longer hospitalizations, and death in the hospital, as evident in our own study (data not shown) and in other studies [3,57,58]. Closing the gaps in knowledge, attitudes, and beliefs could eliminate the disparities in EOL care across physician specialty lines.…”